Tivozanib in the treatment of renal cell carcinoma

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• HowladerNRiesLAMariottoABReichmanMERuhlJCroninKAImproved estimates of cancer-specific survival rates from population-based dataJ Natl Cancer Inst2010102201584159820937991
   PubMedGoogle Scholar
• SakamotoSRyanAJKyprianouNTargeting vasculature in urologic tumors: mechanistic and therapeutic significanceJ Cell Biochem2008103369170817668426
   PubMed Web of Science ®Google Scholar
• LjungbergBHanburyDCKuczykMAEuropean Association of Urology Guideline Group for renal cell carcinomaRenal cell carcinoma guidelineEur Urol20075161502151017408850
   PubMed Web of Science ®Google Scholar
• MotzerRJBanderNHNanusDMRenal-cell carcinomaN Engl J Med1996335128658758778606
   PubMed Web of Science ®Google Scholar
• NegrierSEscudierBLassetCRecombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d’ImmunothérapieN Engl J Med199833818127212789562581
   PubMed Web of Science ®Google Scholar
• MotzerRJMazumdarMBacikJRussoPBergWJMetzEMEffect of cytokine therapy on survival for patients with advanced renal cell carcinomaJ Clin Oncol20001891928193510784634
   PubMed Web of Science ®Google Scholar
• KapoorAKHotteSJCurrent status of cytokine therapy in management of patients with metastatic renal cell carcinomaCan Urol Assoc J20071Suppl 2S28S3318542782
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBARussoPMazumdarMInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol200220128929611773181
   PubMed Web of Science ®Google Scholar
• PalSKWilliamsSJosephsonDYCarmichaelCVogelzangNJQuinnDINovel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigmMol Cancer Ther201211352653722351744
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• CoppinCKollmannsbergerCLeLPorzsoltFWiltTJTargeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trialsBJU Int2011108101556156321952069
   PubMed Web of Science ®Google Scholar
• MotzerRJNosovDEisenTTivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial [abstract]J Clin Oncol201230277s
   Google Scholar
• NosovDAEstevesBLipatovONAntitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinomaJ Clin Oncol201230141678168522493422
   PubMed Web of Science ®Google Scholar
• CliffordSCProwseAHAffaraNABuysCHMaherERInactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesisGenes Chromosomes Cancer19982232002099624531
   PubMed Web of Science ®Google Scholar
• RafiSLydenDBenezraRHattoriKHeissigBVascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?Nat Rev Cancer200221182683512415253
   PubMed Web of Science ®Google Scholar
• HermanJGLatifFWengYSilencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinomaProc Natl Acad Sci USA19949121970097047937876
   PubMed Web of Science ®Google Scholar
• KondoKKaelinWGJrThe von Hippel-Lindau tumor suppressor geneExp Cell Res2001264111712511237528
   PubMed Web of Science ®Google Scholar
• KondoKYaoMYoshidaMComprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parametersGenes Chromosomes Cancer2002341586811921283
   PubMed Web of Science ®Google Scholar
• KondoYShenLIssaJPCritical role of histone methylation in tumor suppressor gene silencing in colorectal cancerMol Cell Biol200323120621512482974
   PubMed Web of Science ®Google Scholar
• YoussefEMChenXQHiguchiEHypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancersCancer Res20046472411241715059893
   PubMed Web of Science ®Google Scholar
• BanksRETirukondaPTaylorCGenetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancerCancer Res20066642000201116488999
   PubMed Web of Science ®Google Scholar
• KucejovaBPeña-LlopisSYamasakiTInterplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinomaMol Cancer Res2011991255126521798997
   PubMed Web of Science ®Google Scholar
• HaddadHRiniBICurrent treatment considerations in metastatic renal cell carcinomaCurr Treat Options Oncol201213221222922410708
   PubMed Web of Science ®Google Scholar
• DuckerGSAtreyaCESimkoJPIncomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitorsOncogene Epub412013
   Web of Science ®Google Scholar
• SulzbacherIBirnerPTräxlerMMarbergerMHaitelAExpression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinomaAm J Clin Pathol2003120110711212866380
   PubMed Web of Science ®Google Scholar
• RiniBISmallEJBiology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinomaJ Clin Oncol20052351028104315534359
   PubMed Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factor: basic science and clinical progressEndocr Rev200425458161115294883
   PubMed Web of Science ®Google Scholar
• LeungDWCachianesGKuangWJGoeddelDVFerraraNVascular endothelial growth factor is a secreted angiogenic mitogenScience19892464935130613092479986
   PubMed Web of Science ®Google Scholar
• GeorgeDJKaelinWGJrThe von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancerN Engl J Med2003349541942112890838
   PubMed Web of Science ®Google Scholar
• KowanetzMFerraraNVascular endothelial growth factor signaling pathways: therapeutic perspectiveClin Cancer Res200612175018502216951216
   PubMed Web of Science ®Google Scholar
• KusmartsevSSuZHeiserAReversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinomaClin Cancer Res200814248270827819088044
   PubMed Web of Science ®Google Scholar
• KoJSRaymanPIrelandJDirect and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrainedCancer Res20107093526353620406969
   PubMed Web of Science ®Google Scholar
• LinJSunXFengBTivozanib biomarker identifies tumor infiltrating myeloid cells contributing to tivozanib resistance in both preclinical models and human renal cell carcinoma [abstract]EJC Supplements20108191
   Google Scholar
• McDermottDFImmunotherapy of metastatic renal cell carcinomaCancer2009115Suppl 10S2298S2305
   Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• BiswasSEisenTImmunotherapeutic strategies in kidney cancer – when TKIs are not enoughNat Rev Clin Oncol20096847848719546865
   PubMed Web of Science ®Google Scholar
• MuldersPVascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanismsBJU Int2009104111585158920053190
   PubMed Web of Science ®Google Scholar
• ShibuyaMVascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-ECancer Sci200394975175612967471
   PubMed Web of Science ®Google Scholar
• NakamuraKTaguchiEMiuraTKRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular propertiesCancer Res200666189134914216982756
   PubMed Web of Science ®Google Scholar
• TaguchiENakamuraKMiuraTShibuyaMIsoeTAnti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor modelCancer Sci200899362363018201272
   PubMed Web of Science ®Google Scholar
• PalSKBergerotPGFiglinRATivozanib: current status and future directions in the treatment of solid tumorsExpert Opin Investig Drugs2012211218511859
   PubMed Web of Science ®Google Scholar
• CotreauMMHaleCLJacobsonLAbsorption, metabolism, and excretion of [14c]-tivozanib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in healthy male participants: a phase I, open-label, mass-balance studyClinical Pharmacology in Drug Development20121102109
   PubMed Web of Science ®Google Scholar
• EskensFAde JongeMJBhargavaPBiologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumorsClin Cancer Res201117227156716321976547
   PubMed Web of Science ®Google Scholar
• EskensFOldenhuisCNBhargavaPA phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors [abstract]J Clin Oncol201129549
   Web of Science ®Google Scholar
• EskensFOldenhuisCNLoosWJFinal results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors [abstract]J Clin Oncol2012304132
   Google Scholar
• BhargavaPEstevesBAl-AdhamiMActivity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT) [abstract]J Clin Oncol2010284599
   Web of Science ®Google Scholar
• MotzerRJEisenTHutsonTEOverall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma [abstract]J Clin Oncol201331Suppl 6350
   Web of Science ®Google Scholar
• MotzerRJNosovDTomczakPEfficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib [abstract]J Clin Oncol201331Suppl 6364
   Web of Science ®Google Scholar
• HutsonTENosovDEisenTSubgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract]J Clin Oncol201331Suppl 6354
   Web of Science ®Google Scholar
• RiniBICohenDPLuDRHypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinibJ Natl Cancer Inst2011103976377321527770
   PubMed Web of Science ®Google Scholar
• CellaDIvanescuCSkaltsaKTreatment benefit of tivozanib hydrochloride versus sorafenib on health-related quality of life (HRQoL) among patients (pts) with advanced/metastatic renal cell carcinoma (mRCC): TIVO-1study results [abstract]J Clin Oncol201331355
   Web of Science ®Google Scholar
• SantosNWengerJBHavrePCombination therapy for renal cell cancer: what are possible options?Oncology2011813–422022922085914
   PubMed Web of Science ®Google Scholar
• SadeghiSGarciaJAOvercoming VEGF resistance in renal cancer: biologic and therapeutic implicationsClin Investig (Lond)201226615621
   Google Scholar
• BlagosklonnyMVAntiangiogenic therapy and tumor progressionCancer Cell200451131714749122
   PubMed Web of Science ®Google Scholar
• CasanovasOHicklinDJBergersGHanahanDDrug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell20058429930916226705
   PubMed Web of Science ®Google Scholar
• HuangDDingYZhouMInterleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinomaCancer Res20107031063107120103651
   PubMed Web of Science ®Google Scholar
• BatchelorTTSorensenAGdi TomasoEAZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsCancer Cell2007111839517222792
   PubMed Web of Science ®Google Scholar
• RiniBSzczylikCTannirNMAMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 studyCancer2012118246152616122692704
   PubMed Web of Science ®Google Scholar
• BergersGSongSMeyer-MorseNBergslandEHanahanDBenefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJ Clin Invest200311191287129512727920
   PubMed Web of Science ®Google Scholar
• EisenTJoensuuHNathanPDRegorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trialLancet Oncol201213101055106222959186
   PubMed Web of Science ®Google Scholar
• YaoXQianCNZhangZFTwo distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implicationsClin Cancer Res200713116116917200351
   PubMed Web of Science ®Google Scholar
• PortaCPaglinoCImarisioIChanges in circulating proangiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patientsOncology201384211512223154434
   PubMed Web of Science ®Google Scholar
• PatelPHSenicoPLCurielREMotzerRJPhase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinomaClin Genitourin Cancer200971242719213664
   PubMed Web of Science ®Google Scholar
• MolinaAMFeldmanDRVossMHPhase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinomaCancer201211871868187621898375
   PubMed Web of Science ®Google Scholar
• NegrierSGravisGPérolDTemsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trialLancet Oncol201112767368021664867
   PubMed Web of Science ®Google Scholar
• HarzstarkALSmallEJWeinbergVKA phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinomaCancer2011117184194420021387258
   PubMed Web of Science ®Google Scholar
• FishmanMNSrinivasSRJHaukeRJPhase Ib study of tivozanib [AV-951] in combination with temsirolimus in patients with renal cell carcinomaIn press2013
   Google Scholar
• KabbinavarFFSrinivasSHaukeRJA phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC) [abstract]J Clin Oncol201129Suppl 733021149657
   PubMed Web of Science ®Google Scholar
• MayerELScheulenMEBeckmanJCombination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study [abstract]J Clin Oncol201129109221300925
   PubMed Web of Science ®Google Scholar
• HutsonTERathmellKHudesGRA phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC) [abstract]J Clin Oncol201230TPS4686
   Web of Science ®Google Scholar
• RobinsonMOFengBNicolettiRRelationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride [abstract]J Clin Oncol201331Suppl 6361
   Web of Science ®Google Scholar
• MotzerRJBacikJMazumdarMPrognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experienceClin Cancer Res20041018 Pt 26302S6303S15448021
   PubMed Web of Science ®Google Scholar
• MotzerRJBhargavaPEstevesBA phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC) [abstract]J Clin Oncol201129Suppl 731021149663
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPAVOREN Trial investigatorsBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol200826335422542818936475
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar